Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20582184 | 0.78 | ALDH1A1 (0.38) | ALDH1A1CASP1ALPLLMNAFFAR4 | |
| SCHEMBL2113726 | 0.76 | MEN1 (0.45) | MAPK1HSD17B10ALDH1A1SMN1; SMN2ALPL | |
| SCHEMBL1396210 | 0.76 | ALDH1A1 (0.44) | ALDH1A1ALPLLMNAHTTNR1H3 | |
| SCHEMBL30645638 | 0.76 | ALDH1A1 (0.44) | ALDH1A1ALPLLMNAHTT | |
| SCHEMBL17627048 | 0.76 | ALDH1A1 (0.44) | ALDH1A1ALPLLMNAHTT | |
| SCHEMBL3051213 | 0.72 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2ALPL | |
| SCHEMBL30475298 | 0.72 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2ALPL | |
| SCHEMBL14858215 | 0.71 | CCNA2 (0.42) | ALDH1A1ALPL | |
| SCHEMBL2634991 | 0.69 | MAP2K4 (0.45) | MAPK1NR1H3 | |
| SCHEMBL30316663 | 0.69 | ALPL (0.39) | HSD17B10ALDH1A1SMN1; SMN2ALPLFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160702-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-11052080-B2 | Kinase inhibitors and methods of use thereof | THE BROAD INSTITUTE, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200061050-A9 | KINASE INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-27 | — | — | US | disclosed |
| US-20190175584-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | BROAD INST INC (US) | 2019-06-13 | — | — | US | disclosed |
| US-9096594-B2 | Kinase inhibitors and methods of use thereof | THE BROAD INSTITUTE, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140107141-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061050-A9 | KINASE INHIBITORS AND METHODS OF USE THEREOF | GSK3B, GSK3A, CSNK1A1 | ALOX15 2952/4885MAPK1 44/4885HSD17B10 731/4885 |
| US-11052080-B2 | Kinase inhibitors and methods of use thereof | GSK3B, GSK3A, CSNK1A1 | ALOX15 3118/4885MAPK1 43/4885HSD17B10 551/4885 |
| US-20140107141-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | GSK3B, GSK3A, CSNK1A1 | ALOX15 2952/4885MAPK1 44/4885HSD17B10 731/4885 |
| US-20220160702-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | GSK3B, GSK3A, CSNK1A1 | ALOX15 3118/4885MAPK1 43/4885HSD17B10 551/4885 |
| US-20190175584-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | GSK3B, GSK3A, CSNK1A1 | ALOX15 2952/4885MAPK1 44/4885HSD17B10 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.